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To the Editor: We completely agree with the critical point of
view expressed by Dr Singh regarding the new challenges
raised by epoetin-a’s copies known as follow-on epoetin.1
However, we would like to stress the point that the
qualification of Wepox (Wockhardt Limited, Mumbai, India)
as a ‘biosimilar’ is probably not fully correct.
We acknowledge that this epoetin’s copy is a follow-on
epoetin (related to US regulatory rules), nevertheless, naming
those products as ‘biosimilars’ could bring some confusion
and misunderstanding in the European Union (EU). As the
patents for epoetin-a have expired recently in the EU and
elsewhere, some pharmaceutical manufacturers have started
developing copies. The European Medicines Agency (EMEA)
has made efforts to establish guidelines2 for the development
and approval of biopharmaceuticals through the biosimilar
pathway for biotechnology derived proteins (rHu-Epo, G-
CSF, y). This pathway is totally different from the
regulations for generic chemically defined drugs.3 At this
time, three rHu-EPO have been accepted as a biosimilar in
the EU by the EMEA after having performed the required
phase I and III comparative studies. To the best of our
knowledge, Wepox has not fulfilled these requirements.
Indeed, according to European biosimilar guidelines for
rHu-Epo,4 the clinical efficacy and safety of biosimilar rHu-
EPO preparations should be demonstrated in at least two
adequately powered, randomized, parallel group clinical trials
in comparison to a reference product.5 As mentioned by the
author, potential differences between biosimilar glycopro-
teins such as rHu-EPO and the originator compounds may
have differences on immunogenicity, pharmacokinetics, and
purity, because of the transgene, the host cell line. The culture
conditions and the purification procedures applied by a
follow-on manufacturer cannot be the same as the original.
According to the EMEA biosimilar guidelines, extensive
comparability testing will be required to demonstrate that the
biosimilar has a comparable profile in terms of quality, safety,
and efficacy as the reference product (physicochemical and
biological properties between production batches (that is,
comparability) and in comparison with a reference product
(that is, similarity)). Although several assays are available,
reliable tests for safety and efficacy still require development
and international standards. Clinical trials and postauthor-
ization pharmacovigilance are essential to guarantee the
product’s safety and efficacy over time. In consequence,
pharmacovigilance, as part of a comprehensive risk manage-
ment plan, is needed to include regular testing for consistent
manufacturing of the drug.
This postauthorization program is an integral part of
biosimilar guideline. From our knowledge, Wepox has not
been developed in accordance with the EMEA biosimilar
guidelines. Therefore, the wording of the authors naming this
product as a ‘biosimilar’ could bring some misunderstanding
in Europe.
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Attaf and Torres suggest that we inappropriately use the
term ‘biosimilar’ to describe Wepox in our paper on pure
red cell aplasia. They suggest that using the term
‘biosimilar’ to describe Wepox might be confusing in the
European Union.1 Further, Attaf and Torres suggest that
clinical efficacy and safety studies and postmarketing
surveillance should be used to differentiate a biosimilar
from a follow-on biologic. Attaf and Torres argue that as
Wepox has not undergone the aforenamed studies it
cannot be described as a biosimilar to epoetin-a. We
humbly disagree. To our knowledge, the terms ‘biosimilar’
and ‘follow-on biologics’ are used interchangeably. Conse-
quently, we believe this is simply an issue of semantics.2,3
Indeed, the European Agency for the Evaluation of
Medicinal Products (EMEA) has taken the position that
biosimilar medicines are follow-on versions of original
biological medicines.3 At this point, it is not possible for us
to critically comment on the postmarketing surveillance
infrastructure adopted by Wokhardt India (the manufac-
turers of Wepox) and whether it adheres to EMEA
guidelines. Although we agree that the EMEA has been
more enlightened than the US Food and Drug Adminis-
tration in addressing the issues related to biosimilars,4
especially with respect to epoetin biosimilars, undergoing
EMEA regulatory approval should not be a prerequisite for
an noninnovator epoetin molecule to be considered a
biosimilar. We believe that ‘the process is product’ concept
for biologics remains a matter of controversy. The key
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message is that agents considered as either biosimilars or
follow-on biologics should be regarded as essentially
different from the innovator biologic by virtue of subtle
differences in the manufacturing and/or purification
process. These agents must undergo formal regulatory
approval and they should be marketed in the context of a
strong pharmacovigilance infrastructure. In this regard,
the EMEA has provided a well-thought-out process for
regulatory approval, and the European Union, like the
United States, has robust pharmacovigilance in place.
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To the Editor: We read with interest the stimulating article
by Ahmed et al.1 on the association of oral hormone
replacement therapy and kidney function in postmenopausal
women.
The authors reported the baseline characteristics of the
groups by categorical hormone therapy use. There was a
significant difference in terms of the use of nonsteroidal anti-
inflammatory drugs and diuretics. The groups namely
‘Estrogen only’ (46.8%) and ‘Progestin only’ (52.5%) had a
higher percentage of patients on diuretics. The percentage of
patients on nonsteroidal anti-inflammatory drugs was higher
(45.3%) in the ‘Estrogen only’ group. The elderly (all 66 years
old or older) made up the entire data population. This makes
the subjects more vulnerable to the effects of both
nonsteroidal anti-inflammatory drugs and diuretics on the
renal function. Although other factors were analyzed in
multivariate analysis, we are surprised that the authors did
not include diuretics in the analysis. These drugs are known
to affect effective circulating volume and renal function.2,3
Logistic regression analysis has shown the greatest decline
of glomerular filtration rate in the ‘Progestin only’ group
(D, 3.98; confidence interval: 0.30, 8.26) followed by the
‘Estrogen only’ group (D, 1.21; confidence interval: 0.28,
2.14), but the ‘Combined group’ had the least decline in
glomerular filtration rate (D, 0.99; confidence interval: 0.56,
2.54) with large confidence intervals.1 They did not offer a
plausible explanation for this discrepancy. We hope that they
have a reasonable explanation for this, or is this just a
statistical finding? It will be interesting to see their results
with the inclusion of diuretic use in the analysis.
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